Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015', provides an overview of the Neuromyelitis Optica (Devic's Syndrome)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuromyelitis Optica (Devic's Syndrome) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuromyelitis Optica (Devic's Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuromyelitis Optica (Devic's Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Neuromyelitis Optica (Devic's Syndrome) Overview 7 Therapeutics Development 8 Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview 8 Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis 9 Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies 10 Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Investigation by Universities/Institutes 11 Neuromyelitis Optica (Devic's Syndrome) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies 15 Neuromyelitis Optica (Devic's Syndrome) - Products under Investigation by Universities/Institutes 16 Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development 17 Acorda Therapeutics, Inc. 17 Alexion Pharmaceuticals, Inc. 18 Chugai Pharmaceutical Co., Ltd. 19 HanAll Biopharma Co., Ltd. 20 MedImmune, LLC 21 Opexa Therapeutics, Inc. 22 Shenzhen Beike Biotechnology Co., Ltd. 23 Shire Plc 24 Takeda Pharmaceutical Company Limited 25 Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 C1 esterase inhibitor (human) - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 dalfampridine ER - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Dendritic Cell Therapy for Central Nervous System Disorders - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 eculizumab - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 HL-161 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 immune globulin (human) - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 MEDI-551 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NU-21101 + NU-21502 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 OPX-212 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SA-237 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Neuromyelitis Optica (Devic's Syndrome) - Recent Pipeline Updates 52 Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones 64 Featured News & Press Releases 64 Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica 64 Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program 65 Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 65 Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles 67 Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion 67 Jul 16, 2013: Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica 68 Jun 27, 2013: Alexion Pharma's Soliris Receives FDA Orphan Drug Designation For Treatment Of Neuromyelitis Optica 68 Oct 09, 2012: Alexion Pharma Announces Presentation Of Phase II Study Data Of Eculizumab In Patients With Relapsing Neuromyelitis Optica At ANA Annual Meeting 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2015 8 Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Acorda Therapeutics, Inc., H1 2015 17 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 18 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 19 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 20 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune, LLC, H1 2015 21 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics, Inc., H1 2015 22 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2015 23 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H1 2015 24 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Assessment by Combination Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Neuromyelitis Optica (Devic's Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
